CLINICAL AND LABORATORY STANDARDS INSTITUTE®

1st Edition

H62

Validation of Assays Performed by Flow Cytometry

This guideline includes validation strategies for cell-based assays performed by flow cytometry. This guideline also includes recommendations for instrument qualification and standardization and assay optimization. It also covers recommended practices for the examination and postexamination phases.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes,* is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

H62-Ed1
October 2021

Validation of Assays Performed by Flow Cytometry

Virginia Litwin, PhD
Teri Oldaker, BS, SCYM(ASCP)CM
Elena Afonina, PhD
Antony C. Bakke, PhD, D(ABMLI), CLS
David Barnett, PhD, FRCPath
Jacqueline M. Cleary, BS, MT(ASCP)
Fiona E. Craig, MD
Lorella Di Donato, PhD
Bruce H. Davis, MD
Thomas N. Denny, MSc
Steven Eck, PhD
Nancy Fine, MT(ASCP)
Alessandra Vitaliti Garami, PhD
Cherie Green, BS
Benjamin Hedley, PhD, SCYM(ASCP)
Shuguang Huang, PhD
Andrea J. Illingworth, MS
Chunjie (Cassie) Jiang, MS(ASCPi)
Mike Keeney, ART, FCSMLS(D)
Wolfgang Kern, MD
Raul Louzao, MPA, BS, MT(ASCP)
Natalia Kokorina, MD
Sarah Maremont, MLS, SCYM(ASCP)CM
Laura Marszalek, BS, MT(ASCP)
Katharine A. Muirhead, PhD
Andy C. Rawstron, PhD, BSc
Ahmad Al Samman, BSc
John L. Schmitz, PhD
Alan M. Stall, PhD
Maryalice Stetler-Stevenson, MD, PhD
Jennifer J. Stewart, PhD
Horacio Vall, CLS, QCYM(ASCP)
Paul K. Wallace, BS, MS, PhD
Lili Wang, PhD
Brent L. Wood, MD, PhD
Yuanxin Xu, MD, PhD

Clinical and Laboratory Standards Institute (CLSI). *Validation of Assays Performed by Flow Cytometry*. 1st ed. CLSI guideline H62 (ISBN 978-1-68440-128-4 [Print]; ISBN 978-1-68440-129-1 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2021.

CLINICAL AND LABORATORY STANDARDS INSTITUTE®

Abstract

Clinical and Laboratory Standards Institute guideline H62–*Validation of Assays Performed by Flow Cytometry* focuses primarily on analytical method validation. There are currently no official guidance documents for the validation of assays performed by flow cytometry. Existing guidance for the validation of biochemical methods for quantifying soluble analytes found in plasma, serum, and urine is not fully applicable for quantification and characterization of cellular measurands. Validation of flow cytometry is challenging because the data generated are not derived from a calibration curve and true reference standards are lacking. Additional topics covered in this guideline include instrument qualification and standardization and assay optimization. It also covers recommended practices for the examination and postexamination phases. The recommendations presented in H62 are applicable to a wide range of flow cytometry laboratories, including basic research facilities, biopharmaceutical companies, medical laboratories, and manufacturers. This guideline provides specific recommendations for the appropriate analytical method validation approach based on the intended use of the data and regulatory and accreditation requirements, if any, associated with this use. H62 is designed to assist any laboratory using flow cytometry, as well as manufacturers, in developing, validating, verifying, controlling, analyzing, and implementing fluorescence cell-based assays.

Suggested Citation

CLSI. *Validation of Assays Performed by Flow Cytometry.* 1st ed. CLSI guideline H62. Clinical and Laboratory Standards Institute; 2021.

H62-Ed1

ISBN 978-1-68440-128-4 (Print)

ISBN 978-1-68440-129-1 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 41, Number 20

Committee Membership

Consensus Council

James R. Petisce, PhD
Chairholder
BD Diagnostic Systems
USA

Tania Motschman, MS, MT(ASCP)SBB
Vice-Chairholder
USA

Deirdre Astin, MS, MT(ASCP)
USA

Anne T. Daley, MS, MT(ASCP)DLM, CMQ/OE(ASQ)CSBB
USA

Avis Danishefsky, PhD
FDA Center for Devices and Radiological Health
USA

Collette Fitzgerald, PhD
Centers for Disease Control and Prevention
USA

Michelle McLean, MS, MT(ASCP), BS
Greiner Bio-One, Inc.
USA

James H. Nichols, PhD, DABCC, FAACC
Vanderbilt University School of Medicine
USA

M. Laura Parnas, PhD, DABCC
Roche Diagnostics
USA

Victoria Petrides, MS
Abbott
USA

Matthew A. Wikler, MD, FIDSA, MBA
IDTD Consulting
USA

Document Development Committee on Validation of Assays Performed by Flow Cytometry

Virginia Litwin, PhD
Chairholder
Caprion Biosciences
Canada

Teri Oldaker, BS, SCYM(ASCP)^{CM}
Vice-Chairholder
USA

Raul Louzao, MPA, BS, MT(ASCP)
Committee Secretary
Duke University
USA

David Barnett, PhD, FRCPath
Sheffield Teaching Hospital NHS Foundation Trust
United Kingdom

Jacqueline M. Cleary, BS, MT(ASCP)
FDA Center for Devices and Radiological Health
USA

Thomas N. Denny, MSc
Duke University Medical Center
USA

Cherie Green, BS
Genentech, Inc.
USA

Mike Keeney, ART, FCSMLS(D)
College of American Pathologists
Canada

Wolfgang Kern, MD
MLL Münchner Leukämielabor GmbH
Germany

Jennifer J. Stewart, PhD
Flow Contract Site Laboratory, LLC
USA

Lili Wang, PhD
National Institute of Standards and Technology
USA

Expert Panel on Hematology and Immunology and Ligand Assay

Kathleen M. Curran, BSMT
Chairholder
New York State Department of Health
USA

Donna D. Castellone, MS
Vice-Chairholder
New York Presbyterian Hospital
USA

Richard J. Baltero, MD, PhD, FCAP
East Carolina University
USA

Francois Depasse, PharmD
Diagnostica Stago
France

Mary J. Doyle, PhD, MS, MT(ASCP)
Instrumentation Laboratory
USA

Ian A. Giles, MD
Sysmex American, Inc.
USA

Paula Keating, PhD, BSc
Canterbury Health Laboratories
New Zealand

Yutaka Nagai, PhD
Nihon Kohden Corporation
Japan

Elizabeth Sheppard, HT(ASCP), MBA
Ventana Medical Systems, Inc.
USA

Elizabeth Stafford, PhD
FDA Center for Devices and Radiological Health
USA

Elizabeth M. Van Cott, MD
Massachusetts General Hospital
USA

Staff

Clinical and Laboratory Standards Institute
USA

David E. Sterry, MT(ASCP)
Project Manager

Laura Martin
Editorial Manager

Catherine E.M. Jenkins, ELS
Editor

Kristy L. Leirer, MS
Editor

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Validation of Assays Performed by Flow Cytometry gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Elena Afonina, PhD
USA

Antony C. Bakke, PhD, D(ABMLI), CLS
USA

Bruce H. Davis, MD
USA

Fiona E. Craig, MD
Mayo Clinic Hospital Phoenix
USA

Lorella Di Donato, PhD
Caprion Biosciences Inc.
Canada

Steven Eck, PhD
Medimmune Inc.
USA

Nancy Fine, MT(ASCP)
Beaumont Health System
USA

Alessandra Vitaliti Garami, PhD
Novartis Pharma AG
Switzerland

Benjamin Hedley, PhD, SCYM(ASCP)
London Health Sciences Centre
Canada

Shuguang Huang, PhD
Stat4ward LLC
USA

Andrea J. Illingworth, MS
Dahl-Chase Pathology Associates PA
USA

Chunjie (Cassie) Jiang, MS(ASCP^{i})
National Institutes of Health
USA

Natalia Kokorina, MD
Beckman Coulter
USA

Raul Louzao, MPA, BS, MT(ASCP)
Duke University
USA

Sarah Maremont, MLS, SCYM(ASCP)^{CM}
Sonora Quest Laboratories/
Laboratory Sciences of Arizona
USA

Laura Marszalek, BS, MT(ASCP)
Northwestern Memorial Hospital
USA

Katharine A. Muirhead, PhD
SciGro, Inc.
USA

Andy C. Rawstron, PhD, BSc,
Leeds Teaching Hospitals NHS Trust
United Kingdom

Ahmad Al Samman, BSc
Hamad Medical Corporation
Qatar

John L. Schmitz, PhD
UNC Chapel Hill
USA

Alan M. Stall, PhD
BD Biosciences
USA

Maryalice Stetler-Stevenson, MD, PhD
National Institutes of Health,
Clinical Center
USA

Horacio Vall, CLS, QCYM(ASCP)
Integrated Oncology
USA

Paul K. Wallace, BS, MS, PhD
Roswell Park Cancer Institute
USA

Brent L. Wood, MD, PhD
University of Washington
Medical Center
USA

Yuanxin Xu, MD, PhD
Alnylam Pharmaceuticals
USA

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Validation of Assays Performed by Flow Cytometry gratefully acknowledge the following organizations who served as special reviewers of this guideline:

International Clinical Cytometry Society (ICCS), Advocacy Committee

American Association of Pharmaceutical Scientists (AAPS), Flow Cytometry Action Program Committee

Contents

Contents (Continued)

Foreword

Multiparametric flow cytometry is one of the leading technologies for cellular analysis because it allows simultaneous detection of numerous characteristics of individual cells with relatively high throughput. Although this technology has been a critical component in medical laboratories and drug development for many years, its importance has increased dramatically in the past few years.

In medical laboratories, flow cytometry became an important platform in the mid-1980s when CD4 T-cell counts became critical measurements in the diagnosis and treatment of AIDS. The importance of flow cytometry continued to grow as flow cytometric methods were used to count $CD34^+$ cells for hematopoietic stem cell transplantation and to guide diagnosis and treatment decisions for leukemia and lymphoma as well as other blood diseases, such as paroxysmal nocturnal hemoglobinuria. More recently, flow cytometry has become a critical tool in the assessment of measurable residual disease in leukemia and lymphoma. Flow cytometric analysis provides a tool to effectively evaluate patients with primary immunodeficiencies and to confirm or establish the immune phenotype of a gene mutation.[1]

In the biopharmaceutical industry, this flexible and powerful platform has been important in supporting biomarkers in all phases of drug development for nearly 20 years. More recently, with the introduction of immunotherapeutic agents, novel vaccines, and cell-based therapies, flow cytometry has become a critical tool supporting every aspect from manufacturing to primary end point determinations in medical development. This heightened role for flow cytometry in both laboratory medicine and drug development has resulted in an increased need for high-quality and validated methods, which in turn has created a need for official guidance from regulatory agencies and accreditation organizations regarding the validation of assays performed by flow cytometry. Because no official guidance exists for validation of assays used in flow cytometry, H62 seeks to fill the need for consensus recommendations.

Because data should be reliable, no matter the intended use, the target audience for this guideline includes nonregulated laboratories such as basic science research laboratories, as well as regulated laboratories. As such, a one-size-fits-all approach to analytical method validation is not appropriate. This guideline presents a fit-for-purpose (FFP) approach to analytical method validation, as described in Chapters 3 and 6. Briefly, the concept of FFP method validation was introduced in 2005 by the American Association of Pharmaceutical Scientists.[2] This publication conveyed the message that although some degree of validation should always be conducted to generate reliable data, the level of validation should be tailored to the intended use of the data. If, as is the case in preclinical or nonclinical settings such as drug development and basic research, the intended use of the data changes, additional validation should be conducted to meet the new intended use and regulatory requirements associated with this use. However, in a clinical environment, the intended use of the data from assays used for clinical diagnosis and longitudinal monitoring would not change. The term "FFP method validation" appears in numerous publications, including *Bioanalytical Method Validation: Guidance for Industry,* which was published in 2018 by the Center for Drug Evaluation and Research, for the US Food and Drug Administration,[3] and should not be misinterpreted as a justification for inadequate validation. H62 presents minimal standards for FFP, as well as analytical validation for a wide variety of intended uses (see Table 22 and Appendix A for more information).

Flow cytometric methods pose unique validation challenges due to the complexity of cellular measurands and the lack of reference materials and because data are not typically derived from a calibration curve. Thus, the existing recommendations for validation of biochemical methods or ligand-binding assays for quantifying soluble analytes found in plasma, serum, and urine cannot be fully applied in the validation of flow cytometric methods for quantifying cellular measurands. In addition to discussing analytical method validation, this guideline provides recommendations for instrument characterization and standardization and assay development and optimization, as well as recommended practices for the examination and postexamination phases. The content is designed to assist laboratories and manufacturers in developing, validating, verifying, controlling, analyzing, and implementing cell-based assays performed by flow cytometry.

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

Cell-based assay
Context of use
Fit-for-purpose
Flow cytometry
Laboratory-developed tests
Standardization
Validation
Verification

Use of Alexa Fluor 488® (succinimidyl ester free acid), Brilliant™ Blue, Brilliant Violet™, PE-Texas Red® (phycoerythrin–sulforhodamine 101 sulfonyl chloride), and SRM® 1934 in this guideline is not an endorsement on the part of CLSI. With each use of the trade name, "or the equivalent" is added to indicate that this guideline also applies to any equivalent products.

Chapter 1

Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Standard precautions information
- Terminology information, including:
  - Terms and definitions used in the guideline
  - Abbreviations and acronyms used in the guideline

Validation of Assays Performed by Flow Cytometry

1 Introduction

1.1 Scope

This guideline focuses on the unique requirements for the analytical validation of cell-based assays performed by flow cytometry, which are not covered in other CLSI documents. Although flow cytometry can be used for a wide variety of applications other than cellular analysis, this guideline focuses on cellular analysis; however, the general principles are also applicable to noncellular particles. Recommendations and practical instructions are provided for preexamination phase activities such as sample requirements, reagent optimization evaluation, instrument qualification and standardization, and assay optimization and validation. Guidance for examination phase activities such as instrument monitoring and QC are described, as are recommended practices for postexamination activities, including data review, reporting, storage, and retention. This guideline is intended for use in a flow cytometry environment in which preclinical (or nonclinical) and clinical assessments are conducted, including but not limited to:

- Research laboratories (academic and nonacademic)
- Medical laboratories
- Drug discovery, development, and manufacturing companies
- Reagent, assay, and instrument manufacturers
- Regulatory agencies

This guideline provides general recommendations but does not discuss details of specific applications, such as lymphocyte immunophenotyping or neoplastic cell or erythrocyte analysis, which are covered in CLSI documents H42,[4] H43,[5] and H52.[6] The validation of flow cytometric assays for noncellular measurands or soluble analytes is beyond the scope of this guideline. Software validation is also beyond the scope of this guideline. For more information about software validation, see CLSI document AUTO13.[7] In a regulated setting, it is highly desirable to use software adhering to 21 CFR Part 11 guidelines[8] whenever possible; however, these features are not supported by many flow cytometry software packages. Manual processes must be used to control noncompliant software functionality or to adopt compliant software packages.

1.2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.[9] For specific precautions required for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.[10]